MRK logo

MERCK & CO. INC.

MRKNYSE
๐Ÿ† #40 by market capEarnings Oct 29 ยท PreUS Equity
$130.34โ–ผ $0.56 (โˆ’0.43%)
Live
1hโ€”
24hโ–ผ 0.4%
7dโ–ฒ 1.8%
14dโ–ผ 1.1%
30dโ–ฒ 5.6%
1yโ–ฒ 62.8%
๐ŸฆMarket Cap
$321.90B
Large Cap
๐Ÿ“ˆRevenue Growth (YoY)
+4.6%
Slowing
๐Ÿ“ŠGross Margin
77.3%
High
๐Ÿ’ตFCF Margin
21.2%
Strong
โš–๏ธP/S Ratio
4.8x
Fair
Otter Score
56
Weak

Trading Snapshot

Day Range
$128.35 โ€“ $132.16
52-Week Range
$77.58 โ€“ $135.05
Volume
$9.96B
Avg Volume
$10.68B
Shares Outstanding
2.47B
Next Earnings
Sep 19, 2026

Fundamentals Snapshot

Annual Revenue
$66.56B
Last Q Revenue
$17.70B
P/E Ratio
100.1
P/S Ratio
4.8x
EPS (TTM)
$1.25
Dividend Yield
2.59%

Why Investors Own MRK

  • โœ“High-growth profile โ€” revenue up +50.7% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 27% gross margin and 9% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$66.56Bโ–ฒ +48.9% YoY
Gross Margin (TTM)
26.6%โ–ผ โˆ’0.2% YoY
Operating Income (TTM)
$5.99Bโ–ฒ +48.9% YoY
Free Cash Flow (TTM)
$6.26Bโ–ฒ +48.9% YoY

About MERCK & CO. INC.

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Weak
56/100

Analyst Ratings

โ“˜
Consensus
Buy
36 analysts
Strong Buy9
Buy16
Hold11
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates